With artificial intelligence (AI) continuing to advance within the pharma industry, it is transforming how new molecules are discovered, developed and delivered.
Offering opportunities to accelerate timelines, reduce experimental burden and improve decision-making throughout the drug development lifecycle, Emily Letton speaks to Quotient Science’s Matt Paterson to explore the topic.
From discovery to development
In target identification, for example, AI algorithms analyse extensive datasets to isolate promising drug targets. For molecule design and screening, simulations can predict compound–target interactions, thereby minimising the need for large-scale physical testing.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.